US FDA advisers back Pfizer-BioNTech Covid-19 vaccine for children

The companies have said their vaccine showed 90.7% efficacy against the coronavirus in a clinical trial of children aged 5 to 11

Manas Mishra and Michael Erman | Reuters
Coronavirus vaccine

Pfizer and BioNTech are seeking clearance for a lower, 10-microgram dose of the vaccine in children, versus 30 micrograms for those age 12 and older

An expert panel on Tuesday voted overwhelmingly to recommend the US Food and Drug Administration authorize the Pfizer Inc and BioNTech SE Covid-19 vaccine for children ages 5 to 11, saying the benefits of inoculation outweigh the risks.
An authorization for that age group would be would be an important regulatory step toward reaching about 28 million children for inoculation, most of them back in school for in-person learning.
The vaccine could be available to the younger age group as soon as next week. The FDA is not obligated to follow the advice of its outside experts, but usually does.

Also Read

Pfizer-BioNTech ask EU agency to approve vaccine for kids 5-11

Canada authorises Pfizer coronavirus vaccine for age 12 and older

Explained: What FDA full approval to Pfizer-BioNTech vaccine means

UK approves Pfizer-BioNtech vaccine for use in 12- to 15-year-olds

US FDA says Pfizer Covid-19 vaccine looks effective for young kids

No nod for Bharat Bio's Covaxin yet, WHO seeks 'additional clarifications'

Over 1.03 billion vaccine doses administered in India so far, says govt

Delhi records 41 Covid-19 cases, zero death; positivity rate at 0.08%

Review of Covaxin underway, expect a recommendation within 24 hours: WHO

Centre asks West Bengal to immediately undertake a review of Covid cases

First Published: Oct 27 2021 | 3:14 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on are available only to BS Premium subscribers. Already a BS Premium subscriber?LOGIN NOW

Register to